Apollo Medicine
A Novel Multimodal Approach in AAU Resistant to Conventional Therapies and Tofacitinib: A Case Report
Introduction: Alopecia areata universalis (AAU) is a long-lasting, chronic, recurrent immune-mediated disease characterised by non-scarring hair loss of the scalp and other hair-bearing body areas. Even when treated with various treatments such as oral and topical steroids, anthralin, phototherapy and tofacitinib, recurrence is common after 6 months to 1 year. AAU presents with well-delineated, circumscribed patches of hair loss of the scalp. Remission is observed in 50% of cases within 1 year. Relapse may occur in …